I-Corps: Natural Compounds for Wound Healing

I-Corps：用于伤口愈合的天然化合物

• 批准号: 1811949
• 负责人: Ehsan Jabbarzadeh
• 金额: $ 5万
• 依托单位: University of South Carolina at Columbia
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-01 至 2018-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1811949&HistoricalAwards=false
• 关键词: Corps; Natural; Compounds; Wound; Healing

The broader impact/commercial potential of this I-Corps project is providing affordable and effective method to treat chronic wounds based on the use of two natural compounds. Chronic wounds affect millions of people in US and account for a significant fraction of overall health care costs. Nevertheless, the regeneration of skin remains a huge challenge due to its multilayered structure and the presence of different cell types organized within the extracellular matrix. This complexity necessitates the use of multi-functional drugs with antioxidant, anti-inflammatory, anti-microbial, pro-angiogenesis and pro-healing properties. The potential advantages of the proposed treatment strategy over conventional approaches include reduced cost, decreased side-effects, lower risk of infection, and increased patient compliance.This I-Corps project core technology is a chronic wound healing product composed of two phenolic compounds isolated from a botanical source to yield an active source of anti-inflammatory, pro-angiogenic and pro-regeneration activities. Chronic wound healing is a complex physiological process controlled by a well-orchestrated cascade of interdependent biochemical and cellular events. The proposed innovation harnesses the multi-targeting ability of natural compounds to modulate the crosstalk between inflammation, epithelialization and vascular formation in chronic wounds. The team will potentially develop a minimum viable product based on a proprietary formulation of phenolic natural compounds to accelerate fibroblast and keratinocytes migration, enhance blood vessel formation, and modulate macrophage response. The scope of this project is not necessarily confined to the field of wound repair. Unraveling the cellular and molecular modes of action that regulate immunomodulatory signaling cascades is an important step in drug discovery with a wide array of potential applications.

I-Corps项目的更广泛的影响/商业潜力是提供负担得起的有效方法来治疗基于两种天然化合物的慢性伤口。在美国，慢性伤口影响着数百万人，占总医疗费用的很大一部分。然而，由于皮肤的多层结构和细胞外基质中不同类型细胞的存在，皮肤的再生仍然是一个巨大的挑战。这种复杂性要求使用具有抗氧化、抗炎、抗微生物、促血管生成和促愈合特性的多功能药物。与传统方法相比，拟议的治疗策略的潜在优势包括降低成本、减少副作用、降低感染风险和提高患者依从性。这项I-Corps项目的核心技术是一种慢性伤口愈合产品，由从植物来源分离的两种酚类化合物组成，产生抗炎、促血管生成和促再生活性的活性来源。慢性创面愈合是一个复杂的生理过程，由一系列相互依赖的生化和细胞事件控制。这项拟议的创新利用天然化合物的多靶向能力来调节慢性伤口炎症、上皮化和血管形成之间的串扰。该团队可能会开发一种基于酚类天然化合物专利配方的最低可行产品，以加速成纤维细胞和角质形成细胞的迁移，增强血管形成，并调节巨噬细胞的反应。这个项目的范围不一定局限于伤口修复领域。解开调节免疫调节信号级联的细胞和分子作用模式是药物发现中的重要一步，具有广泛的潜在应用。